<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12914">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00442611</url>
  </required_header>
  <id_info>
    <org_study_id>100 186</org_study_id>
    <nct_id>NCT00442611</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)</brief_title>
  <official_title>A Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic sclerosis (scleroderma) is an autoimmune connective tissue disease that involves
      the skin and other internal organs for which there are few effective treatment options. We
      hypothesize that treatment with abatacept, a new therapy recently approved for the treatment
      of rheumatoid arthritis, may reduce the progression of skin thickening and fibrosis in
      people with scleroderma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic sclerosis is an autoimmune connective tissue disease of unknown etiology
      characterized by progressive fibrosis of the skin and internal organs, vascular damage, and
      autoantibody production. Although the disease is relatively rare, it is associated with
      considerable morbidity and mortality. There have been improvements in survival over the past
      few decades; however, this has been related to better management of vascular manifestations
      of disease including renal crisis, pulmonary hypertension, gastroesophageal reflux disease,
      and Raynaud's phenomenon. Clinical studies of disease modifying therapies for cutaneous
      disease to date have been relatively unsuccessful.

      Although the etiology of the disease remains unknown, several observations support the role
      of activated T cells in both the blood and skin of affected patients. Abatacept, a
      recombinant fusion protein that blocks T cell activation, has recently been approved by the
      FDA for rheumatoid arthritis. We hypothesize that inhibition of T cell activation with
      abatacept may be efficacious in the treatment of patients with diffuse systemic sclerosis.
      This is a randomized, double-blinded, placebo-controlled clinical trial of abatacept versus
      placebo in patients with diffuse systemic sclerosis. Changes in validated measures of skin
      thickness and disease activity over 6-months of treatment will be compared between patients
      receiving abatacept and those receiving placebo. Patients will be randomized 2:1 to receive
      abatacept.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Modified Rodnan Skin Score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Modified Rodnan Skin Score measures skin thickness and is the sum of scores from 17 surface anatomic areas rated on a 0-3 scale (0=normal skin; 1=mild thickness; 2=moderate thickness; 3=severe thickness with inability to pinch the skin into a fold). Total modified Rodnan Skin Score ranges from 0 (best possible outcome) to 51 (worst possible outcome).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Oral Aperture and Hand Extension</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary Function Tests</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>FVC (Forced Vital Capacity) is the amount of air that can be forcibly exhaled from the lungs after taking the deepest possible breath.
DLCO (Diffusing capacity of the lung for carbon monoxide) is the extent to which oxygen passes from the lungs to the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Digital Ulcerations</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Scleroderma Health Assessment Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The HAQ-DI includes 20 items in 8 functional domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities) assessing the patient's usual abilities in the past seven days. Each item is scored on a 0-3 scale (0=without any difficulty; 1=with some difficulty; 2=with much difficulty; 3=unable to do). The use of assistive devices for any domain increases the domain score by 1 point to a maximum of 3. The overall score is calculated by summing the highest item score in each of the domains and dividing the sum by 8, with an overall score of 0 indicating no disability, and a score of 3 indicating severe disability.
The time points compared were 6 months to baseline (6 months minus baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Autoantibody Profile</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Cytokine Profile</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Scleroderma, Diffuse</condition>
  <condition>Scleroderma, Systemic</condition>
  <arm_group>
    <arm_group_label>Abatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug, Abatacept, will be administered in a double-blind fashion to the active arm of the study. It will be administered intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV fluid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo arm will receive matched intravenous fluids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>Active drug, abatacept, will be administered intravenously in a blinded fashion</description>
    <arm_group_label>Abatacept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>Abatacept will be administered, dosed based upon weight, intravenously on days 1, 15, 30 and monthly thereafter for a total of 7 doses.</description>
    <arm_group_label>Abatacept</arm_group_label>
    <arm_group_label>IV fluid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of diffuse systemic sclerosis

          -  age 18 years or older

          -  Adequate renal, pulmonary, and cardiovascular function

          -  Willingness to use effective contraception for the duration of the study if subject
             is of childbearing potential&amp;#xA;

        Exclusion Criteria:

          -  Other connective tissues diseases or overlap syndromes including MCTD, SLE, RA,
             eosinophilic fasciitis, and limited systemic sclerosis or morphea

          -  Use of disease modifying agents including methotrexate, cyclosporine,azathioprine,
             mycophenolate mofetil, minocycline, doxycycline, minocycline, thalidomide,
             penicillamine, tamoxifen, colchicine, or investigational agent within 90 days of
             screening visit

          -  HIV, Hepatitis B or Hepatitis C infection

          -  use of prednisone greater than 10mg daily for 28 days prior to screening visit

          -  women who are breastfeeding or pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eliza Farmer Chakravarty</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 23, 2015</lastchanged_date>
  <firstreceived_date>March 1, 2007</firstreceived_date>
  <firstreceived_results_date>January 26, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Lorinda S Chung</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Abatacept</title>
          <description>Study drug, Abatacept, will be administered in a double-blind fashion to the active arm of the study. It will be administered intravenously.
Abatacept: Active drug, abatacept, will be administered intravenously in a blinded fashion
Abatacept: Abatacept will be administered, dosed based upon weight, intravenously on days 1, 15, 30 and monthly thereafter for a total of 7 doses.</description>
        </group>
        <group group_id="P2">
          <title>IV Fluid</title>
          <description>The placebo arm will receive matched intravenous fluids.
Abatacept: Abatacept will be administered, dosed based upon weight, intravenously on days 1, 15, 30 and monthly thereafter for a total of 7 doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Abatacept</title>
          <description>Study drug, Abatacept, will be administered in a double-blind fashion to the active arm of the study. It will be administered intravenously.
Abatacept: Active drug, abatacept, will be administered intravenously in a blinded fashion
Abatacept: Abatacept will be administered, dosed based upon weight, intravenously on days 1, 15, 30 and monthly thereafter for a total of 7 doses.</description>
        </group>
        <group group_id="B2">
          <title>IV Fluid</title>
          <description>The placebo arm will receive matched intravenous fluids.
Abatacept: Abatacept will be administered, dosed based upon weight, intravenously on days 1, 15, 30 and monthly thereafter for a total of 7 doses.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="39.8" spread="11.4"/>
                <measurement group_id="B2" value="48.6" spread="13.9"/>
                <measurement group_id="B3" value="44.2" spread="12.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Modified Rodnan Skin Score</title>
        <description>Modified Rodnan Skin Score measures skin thickness and is the sum of scores from 17 surface anatomic areas rated on a 0–3 scale (0=normal skin; 1=mild thickness; 2=moderate thickness; 3=severe thickness with inability to pinch the skin into a fold). Total modified Rodnan Skin Score ranges from 0 (best possible outcome) to 51 (worst possible outcome).</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>Study drug, Abatacept, will be administered in a double-blind fashion to the active arm of the study. It will be administered intravenously.
Abatacept: Active drug, abatacept, will be administered intravenously in a blinded fashion
Abatacept: Abatacept will be administered, dosed based upon weight, intravenously on days 1, 15, 30 and monthly thereafter for a total of 7 doses.</description>
          </group>
          <group group_id="O2">
            <title>IV Fluid</title>
            <description>The placebo arm will receive matched intravenous fluids.
Abatacept: Abatacept will be administered, dosed based upon weight, intravenously on days 1, 15, 30 and monthly thereafter for a total of 7 doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Modified Rodnan Skin Score</title>
            <description>Modified Rodnan Skin Score measures skin thickness and is the sum of scores from 17 surface anatomic areas rated on a 0–3 scale (0=normal skin; 1=mild thickness; 2=moderate thickness; 3=severe thickness with inability to pinch the skin into a fold). Total modified Rodnan Skin Score ranges from 0 (best possible outcome) to 51 (worst possible outcome).</description>
            <units>MRSS score</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-8.6" spread="7.5"/>
                  <measurement group_id="O2" value="-2.3" spread="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Oral Aperture and Hand Extension</title>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pulmonary Function Tests</title>
        <description>FVC (Forced Vital Capacity) is the amount of air that can be forcibly exhaled from the lungs after taking the deepest possible breath.
DLCO (Diffusing capacity of the lung for carbon monoxide) is the extent to which oxygen passes from the lungs to the blood.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>Study drug, Abatacept, will be administered in a double-blind fashion to the active arm of the study. It will be administered intravenously.
Abatacept: Active drug, abatacept, will be administered intravenously in a blinded fashion
Abatacept: Abatacept will be administered, dosed based upon weight, intravenously on days 1, 15, 30 and monthly thereafter for a total of 7 doses.</description>
          </group>
          <group group_id="O2">
            <title>IV Fluid</title>
            <description>The placebo arm will receive matched intravenous fluids.
Abatacept: Abatacept will be administered, dosed based upon weight, intravenously on days 1, 15, 30 and monthly thereafter for a total of 7 doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Pulmonary Function Tests</title>
            <description>FVC (Forced Vital Capacity) is the amount of air that can be forcibly exhaled from the lungs after taking the deepest possible breath.
DLCO (Diffusing capacity of the lung for carbon monoxide) is the extent to which oxygen passes from the lungs to the blood.</description>
            <units>% Predicted</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>FVC % Predicted</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.3" spread="8.5"/>
                  <measurement group_id="O2" value=".3" spread="8.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DLCO % Predicted</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" spread="6.3"/>
                  <measurement group_id="O2" value="-7.4" spread="10.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Digital Ulcerations</title>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Scleroderma Health Assessment Questionnaire</title>
        <description>The HAQ-DI includes 20 items in 8 functional domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities) assessing the patient’s usual abilities in the past seven days. Each item is scored on a 0-3 scale (0=without any difficulty; 1=with some difficulty; 2=with much difficulty; 3=unable to do). The use of assistive devices for any domain increases the domain score by 1 point to a maximum of 3. The overall score is calculated by summing the highest item score in each of the domains and dividing the sum by 8, with an overall score of 0 indicating no disability, and a score of 3 indicating severe disability.
The time points compared were 6 months to baseline (6 months minus baseline).</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>Study drug, Abatacept, will be administered in a double-blind fashion to the active arm of the study. It will be administered intravenously.
Abatacept: Active drug, abatacept, will be administered intravenously in a blinded fashion
Abatacept: Abatacept will be administered, dosed based upon weight, intravenously on days 1, 15, 30 and monthly thereafter for a total of 7 doses.</description>
          </group>
          <group group_id="O2">
            <title>IV Fluid</title>
            <description>The placebo arm will receive matched intravenous fluids.
Abatacept: Abatacept will be administered, dosed based upon weight, intravenously on days 1, 15, 30 and monthly thereafter for a total of 7 doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Scleroderma Health Assessment Questionnaire</title>
            <description>The HAQ-DI includes 20 items in 8 functional domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities) assessing the patient’s usual abilities in the past seven days. Each item is scored on a 0-3 scale (0=without any difficulty; 1=with some difficulty; 2=with much difficulty; 3=unable to do). The use of assistive devices for any domain increases the domain score by 1 point to a maximum of 3. The overall score is calculated by summing the highest item score in each of the domains and dividing the sum by 8, with an overall score of 0 indicating no disability, and a score of 3 indicating severe disability.
The time points compared were 6 months to baseline (6 months minus baseline).</description>
            <units>HAQ-DI score</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.04" spread=".24"/>
                  <measurement group_id="O2" value=".25" spread=".25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Autoantibody Profile</title>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Cytokine Profile</title>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Abatacept</title>
          <description>Study drug, Abatacept, will be administered in a double-blind fashion to the active arm of the study. It will be administered intravenously.
Abatacept: Active drug, abatacept, will be administered intravenously in a blinded fashion
Abatacept: Abatacept will be administered, dosed based upon weight, intravenously on days 1, 15, 30 and monthly thereafter for a total of 7 doses.</description>
        </group>
        <group group_id="E2">
          <title>IV Fluid</title>
          <description>The placebo arm will receive matched intravenous fluids.
Abatacept: Abatacept will be administered, dosed based upon weight, intravenously on days 1, 15, 30 and monthly thereafter for a total of 7 doses.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Infected toe digital ulcer</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>lower extremity edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lorinda Chung</name_or_title>
      <organization>Stanford University</organization>
      <phone>(650)493-5000 ext 6242</phone>
      <email>shauwai@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
